UK Industry Body Says NICE Appraisal Changes Don’t Go Far Enough
Executive Summary
NICE, the health technology appraisal institute in the UK, should consider other changes to its appraisal processes beyond increasing efficiency, according to the Association of the British Pharmaceutical Industry.
You may also be interested in...
NICE Proposals To Cut Patient Input Under Fire In UK
Proposals from UK HTA body NICE that aim to increase capacity to meet the growing demand for appraisals have come under fire for downgrading the role of patients and clinicians.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.